Technology Platform I
Universal CAR NK engineered with base editing to target
cellular senescence and tumors
Technology Platform II
Human bioenergy based biophysical and digital therapy
Technology Platform III
Novel LNP/mRNA nanovaccines for CNS and cancer
Pipeline
Anti-Aging
LIFE Sciences Corp is determined to extend human lifespan by 30 years through three key approaches:
-
Anti-aging intranasal nanovaccine and nanomedicine for Alzheimer's & Parkinson's.
-
Human bioenergy based digital therapy for Parkinson's Disease.
-
Calorie restriction mimics targeting mitochondrial metabolism.
We also utilize immuno-senolytic CAR NK targeting cellular senescence (aging cells) for the treatment of cardiomyopathy.
Cell and gene therapy: blood Tumor
Cell and gene therapy: solid Tumor
MKureTM for the treatment of BCMA exposed/relapsed MM is a CAR-NK therapy which contains a proprietary GPRC5D nanobody derived from llama. Pending in vivo efficacy and safety data in animals, NKLife plans for an IND submission in both US and China in 1H24. MKureTM has a strong IP portfolio which consists of the GPRC5D nanobody, the genetically designed CAR sequence, and the proprietary technology involved in bioprocessing NK cells from healthy donors.
BKURETM is a CAR-NK with a llama derived nanobody against ROR1 for the treatment of triple negative breast cancer.
GKURETM is a CAR-NK with a llama derived nanobody raised against Claudin18.2 for the treatment of gastric cancer.
Management
Formed in September 2021 by five scientists with Merck, J&J, Rutgers, Rockefeller and Sloan Kettering backgrounds
Lei Zhong, PhD. CEO
Pace Yang, PhD. COO
Charlie Gong, PhD. CTO
Victor Jin, PhD. CSO (Interim)
Ping Peng, PhD. CDO (Interim)
Cai Zen, MD. PhD. Chief Medical Advisor
Call us a little crazy, but we have ways to add 30yrs of healthy life to all
Milestones
Scroll to learn about our company’s journey
LIFE
